Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.

MLA

Necchi, Andrea, et al. “Pembrolizumab Monotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer without Carcinoma in Situ and Unresponsive to BCG (KEYNOTE-057): A Single-Arm, Multicentre, Phase 2 Trial.” Lancet Oncology, vol. 25, no. 6, June 2024, pp. 720–30. EBSCOhost, https://doi.org/10.1016/S1470-2045(24)00178-5.

APA

Necchi, A., Roumiguié, M., Kamat, A. M., Shore, N. D., Boormans, J. L., Esen, A. A., Lebret, T., Kandori, S., Bajorin, D. F., Krieger, L. E. M., Niglio, S. A., Uchio, E. M., Seo, H. K., de Wit, R., Singer, E. A., Grivas, P., Nishiyama, H., Li, H., Baranwal, P., & Van den Sigtenhorst-Fijlstra, M. (2024). Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncology, 25(6), 720–730. https://doi.org/10.1016/S1470-2045(24)00178-5

Chicago

Necchi, Andrea, Mathieu Roumiguié, Ashish M Kamat, Neal D Shore, Joost L Boormans, Ahmet Adil Esen, Thierry Lebret, et al. 2024. “Pembrolizumab Monotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer without Carcinoma in Situ and Unresponsive to BCG (KEYNOTE-057): A Single-Arm, Multicentre, Phase 2 Trial.” Lancet Oncology 25 (6): 720–30. doi:10.1016/S1470-2045(24)00178-5.